To evaluate the association of fetal growth parameters and cardiac ejection fraction in women with peripartum cardiomyopathy and hereditary cardiomyopathy. STUDY DESIGN: This was a retrospective cohort analysis of 34 singleton pregnancies complicated by maternal hereditary or peripartum cardiomyopathy in Kansas City between 2004 and 2015. Institutional Review Board approval was obtained at St. Luke's Hospital of Kansas City. These women were stratified by the World Health Organization (WHO) classification of maternal cardiovascular risk, CARPREG scores, and lowest ejection fraction measured during pregnancy. Fetal growth parameters were assessed with third trimester ultrasound and birth weight percentiles. Demographics, gestational age, delivery mode, ultrasound parameters, echocardiogram measurements, maternal and neonatal complications were also collected. Data was analyzed using Student's T-test, chi-square or Fisher's exact test. RESULTS: Fetal growth parameters for the entire cohort were overall normal, with normal third trimester estimated fetal weight percentiles and birth weight percentiles (45+/-26% and 54.6+/-25.9% respectively), with only 3.2% of the population meeting criteria for growth restriction. The average gestational age at delivery was 38.1 weeks. When stratified by maternal cardiac risk there was no association with CARPREG scores (greater than 1) or WHO risk scores (greater than 2) and fetal growth patterns. Pregnancies were also stratified by ejection fractions <35% and >35%, which did not show significance. This was not altered when stratifying patients into history of peripartum cardiomyopathy or hereditary cardiomyopathy. There were no other parameters that were associated with fetal growth restriction in this cohort. CONCLUSION: Cardiac output and function are believed to have an impact on fetal growth. Optimal strategies on antenatal surveillance, growth ultrasounds, and management have not been established. This study did not find an association with cardiomyopathy and growth restriction. Incidentally, fewer growth restricted infants were found than would be expected in the general population, however, this study is limited by the sample size. Future studies are needed to further elucidate the association of cardiomyopathy and heart function on fetal growth to provide evidence-based guidance on antenatal surveillance and counseling in this high risk population.
OBJECTIVE:
To evaluate the association of fetal growth parameters and cardiac ejection fraction in women with peripartum cardiomyopathy and hereditary cardiomyopathy. STUDY DESIGN: This was a retrospective cohort analysis of 34 singleton pregnancies complicated by maternal hereditary or peripartum cardiomyopathy in Kansas City between 2004 and 2015. Institutional Review Board approval was obtained at St. Luke's Hospital of Kansas City. These women were stratified by the World Health Organization (WHO) classification of maternal cardiovascular risk, CARPREG scores, and lowest ejection fraction measured during pregnancy. Fetal growth parameters were assessed with third trimester ultrasound and birth weight percentiles. Demographics, gestational age, delivery mode, ultrasound parameters, echocardiogram measurements, maternal and neonatal complications were also collected. Data was analyzed using Student's T-test, chi-square or Fisher's exact test. RESULTS: Fetal growth parameters for the entire cohort were overall normal, with normal third trimester estimated fetal weight percentiles and birth weight percentiles (45+/-26% and 54.6+/-25.9% respectively), with only 3.2% of the population meeting criteria for growth restriction. The average gestational age at delivery was 38.1 weeks. When stratified by maternal cardiac risk there was no association with CARPREG scores (greater than 1) or WHO risk scores (greater than 2) and fetal growth patterns. Pregnancies were also stratified by ejection fractions <35% and >35%, which did not show significance. This was not altered when stratifying patients into history of peripartum cardiomyopathy or hereditary cardiomyopathy. There were no other parameters that were associated with fetal growth restriction in this cohort. CONCLUSION: Cardiac output and function are believed to have an impact on fetal growth. Optimal strategies on antenatal surveillance, growth ultrasounds, and management have not been established. This study did not find an association with cardiomyopathy and growth restriction. Incidentally, fewer growth restricted infants were found than would be expected in the general population, however, this study is limited by the sample size. Future studies are needed to further elucidate the association of cardiomyopathy and heart function on fetal growth to provide evidence-based guidance on antenatal surveillance and counseling in this high risk population. OBJECTIVE: Chemotherapy exposure during pregnancy has been variably associated with adverse outcomes, including growth restriction. We sought to confirm this association and evaluate impact by the type, gestational age (GA) at initiation, and duration of chemotherapy. We also assessed whether growth restriction is correlated with placental pathology. STUDY DESIGN: Our cohort included women diagnosed with breast cancer in pregnancy (BCP) between 1996-2017 at three academic centers. Univariate and regression analyses were used to analyze oncologic treatment and obstetric outcomes. Primary outcomes were neonatal birthweight, controlled for GA at delivery, and small for gestational age infant (SGA). Preplanned sensitivity analyses were performed. RESULTS: The cohort included 110 women with BCP who had a singleton live birth; 64 (58.2%) had complete obstetric and 45 (40.9%) placental data available. Sixty-three (57.8%) received chemotherapy in pregnancy, consisting of doxorubicin and cyclophosphamide (AC) and taxanes (T) (Figure 1) . Median GA at chemotherapy initiation was 22 weeks. There was no difference in GA at delivery between those who did and did not receive chemotherapy (36.9 vs 37.3 weeks, p¼0.34). Chemotherapy was associated with lower birthweight (2740g vs 3022g, p¼0.037) but not increased SGA (21% vs 10%, p¼0.49). Taxane exposure specifically was associated with decreased birthweight (p¼0.04) but also longer chemotherapy duration (9.8 vs 17.4 wks, p<0.001). Earlier GA at chemotherapy initiation was associated with increased SGA (p¼0.027), which persisted when controlling for length of exposure (p¼0.022). Placental weight was lower in the group exposed to chemotherapy (390g vs 480g, p¼0.046), and smaller placentas were associated with SGA (p<0.01); however, there was no difference in the rate of placental infarct, hematoma, or chorioamnionitis (37.5% vs 42.1%, p¼1.0). Composite obstetrical outcomes (p¼0.53) and neonatal outcomes (p¼0.12) did not differ by chemotherapy exposure (Table 1) . CONCLUSION: Chemotherapy for BCP was associated with decreased neonatal birthweight and placental weight, but similar rates of SGA and placental lesions. Lower birthweights were associated with earlier initiation of chemotherapy and taxane exposure, but the latter is confounded by longer duration of chemotherapy. This raises further questions about mediators of growth restriction in women exposed to chemotherapy in BCP.
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